J Endocrinol Metab
Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Letter to the Editor

Volume 7, Number 3, June 2017, pages 98-99


Construction of Effective and Safe Glycemic Control in the Elderly by Using Continuous Glucose Monitoring

Koki Kakutaa, b, Hiroki Adachia, b, Hidekatsu Yanaia, c

aDepartment of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan
bThese authors equally contributed to this work.
cCorresponding Author: Hidekatsu Yanai, Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa, Chiba 272-0034, Japan

Manuscript submitted May 16, 2017, accepted May 30, 2017
Short title: Letter to the Editor
doi: https://doi.org/10.14740/jem425w

To the Editor▴Top 

Severe hypoglycemia is significantly associated with increased risks of a range of adverse clinical outcomes [1]. An increased risk for developing dementia by older patients with diabetes who have had episode of severe hypoglycemia has been suggested [2]. Further, patients with dementia and diabetes appear to be at greater risk for severe hypoglycemia [2]. However, excellent evidence on glycemic control in the elderly is lacking, and optimal treatment needs to be constructed collaboratively with patients, incorporating the likelihood of benefits and harms and patients preferences about treatment in older adults with type 2 diabetes [3].

To show the usefulness of continuous glucose monitoring (CGM) to determine safe and effective glycemic control in the elderly, we present our old patient who showed asymptomatic severe hypoglycemia during sleeping. An 83-year-old type 2 diabetic female patient (body height, 151.4 cm; body weight, 56.7 kg; BMI, 24.7 kg/m2) was admitted to our hospital due to poor glycemic control. She has been treated by ingestion of alogliptin (25 mg) before breakfast, and repaglinide (1.0 mg) before every meal, and injection of insulin glargine U300 (10 U) before breakfast. On admission, her plasma glucose and HbA1c level were 334 mg/dL and 8.7%, respectively.

We changed insulin treatment from insulin glargine U300 (10 U) to insulin degludec (IDeg)/insulin aspart (IAsp) (14 U) which is a soluble conformation of two distinct insulin analogues in the ratio of 70% ultra-long-acting IDeg and 30% rapid-acting IAsp [4]. We stopped ingestion of repaglinide before breakfast because of the addition of IAsp before breakfast. We also switched from repaglinide (1.0 mg before lunch and dinner) to α-glucosidase inhibitor (α-GI), voglibose (0.3 mg before lunch and dinner).

We present the result of CGM which showed the effect of switching from repaglinide to voglibose on glycemic control in Figure 1. CGM showed hypoglycemia early at morning (from 2 to 6 o’clock in the morning) (Fig. 1a, b) during the treatment using repaglinide. After the switching to voglibose, hypoglycemia early at morning was disappeared (Fig. 1c, d). In addition, maximal glucose level and amplitude of glucose excursion decreased, in spite of reduction of insulin dose (Fig. 1d).

Figure 1.
Click for large image
Figure 1. Continuous glucose monitoring showing the effect of switching from repaglinide to voglibose for the treatment for type 2 diabetes in old women.

Repaglinide is a short-acting, insulin-releasing agent, and has been suggested to lessen the risk of long-lasting hypoglycemia [5], however, which was observed in our patient. We should consider the development of severe hypoglycemia in the elderly whose drug clearance is diminished when we use glinides. Furthermore, our observation indicated that α-GI does not induce long-lasting hypoglycemia and also ameliorates glycemic control in combination with insulin as compared with glinides.

We think that benefits and harms about treatment for diabetes depend largely on individuals, and individual differences get larger by aging. Therefore, we strongly recommend the construction of safe and effective glycemic control in the elderly by using CGM.

Conflicts of Interest

The authors declare that they have no conflicts of interest concerning this article.


References▴Top 
  1. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418.
    doi pubmed
  2. Meneilly GS, Tessier DM. Diabetes, Dementia and Hypoglycemia. Can J Diabetes. 2016;40(1):73-76.
    doi pubmed
  3. Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA. 2016;315(10):1034-1045.
    doi pubmed
  4. Ma Z, Parkner T, Christiansen JS, Laursen T. IDegAsp: a novel soluble insulin analogs combination. Expert Opin Biol Ther. 2012;12(11):1533-1540.
    doi pubmed
  5. Guay DR. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy. 1998;18(6):1195-1204.
    pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Endocrinology and Metabolism is published by Elmer Press Inc.

 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!